News

STAT9h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Devdiscourse7h
Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...
Healio7h
Once-monthly dosing of novel GLP-1 agonist/GIP antagonist yields substantial weight loss
Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...
New Data Shows Just How Powerful the Next Weight-Loss Drugs May Be
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
New Formulations of GLP-1s Demonstrate Positive Results, Potentially Offering Additional Options for Obesity Medications
Findings from two breakthrough studies reveal positive outcomes for two medications - orfoglipron and MariTide (maridebart cafraglutide) – expanding the treatment of type two diabetes and obesity.